Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Small

Showing results (111-120 of 361) with videos related to

Pageof 37
Sort By:
Clinical Genitourinary Cancer|May 30, 2006
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480Peter A Humphrey, Susan Halabi, Joel Picus, et al.
Journal of the National Cancer Institute|July 25, 2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancerPhilip W Kantoff, Celestia S Higano, Eric J Small, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsSerena S Kwek, Vinh Dao, Ritu Roy, et al.
Investigational New Drugs|April 27, 2007
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)Charles J Ryan, Walter M Stadler, Bruce Roth, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George, Susan Halabi, Timothy F Shepard, et al.
Cancer|April 27, 2012
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809Mark D Hurwitz, Susan Halabi, Laura Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Pain predicts overall survival in men with metastatic castration-refractory prostate cancerSusan Halabi, Nicholas J Vogelzang, Alice B Kornblith, et al.
The Journal of Urology|September 20, 2008
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapyWalter J Urba, John Nemunaitis, Fray Marshall, et al.
Pageof 37

Showing results (111-120 of 361) with videos related to

Sort By:
Pageof 37
Clinical Genitourinary Cancer|May 30, 2006
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480Peter A Humphrey, Susan Halabi, Joel Picus, et al.
Journal of the National Cancer Institute|July 25, 2012
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancerPhilip W Kantoff, Celestia S Higano, Eric J Small, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 8, 2012
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patientsSerena S Kwek, Vinh Dao, Ritu Roy, et al.
Investigational New Drugs|April 27, 2007
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)Charles J Ryan, Walter M Stadler, Bruce Roth, et al.
Cancer|August 16, 2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Walter M Stadler, Susan Halabi, Brian Rini, et al.
Cancer|December 12, 2003
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813William K Oh, Susan Halabi, W Kevin Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 10, 2005
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480Daniel J George, Susan Halabi, Timothy F Shepard, et al.
Cancer|April 27, 2012
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809Mark D Hurwitz, Susan Halabi, Laura Archer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Pain predicts overall survival in men with metastatic castration-refractory prostate cancerSusan Halabi, Nicholas J Vogelzang, Alice B Kornblith, et al.
The Journal of Urology|September 20, 2008
Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapyWalter J Urba, John Nemunaitis, Fray Marshall, et al.
Pageof 37